Lyell Immunopharma Inc (LYEL) — Capital Reinvestment Ratio
Latest as of December 2019:
0.41x
Lyell Immunopharma Inc (LYEL) has a Capital Reinvestment Ratio of 0.41x as of December 2019, meaning it reinvests 0% of its operating cash flow ($39.47 Million) in capital expenditures ($16.05 Million). See LYEL free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.41x
Capex / Operating Cash Flow
Operating Cash Flow
$39.47 Million
USD
Capital Expenditures
$16.05 Million
USD
Data as of
Dec 2019
Most recent filing
Lyell Immunopharma Inc Capital Reinvestment Ratio (2019–2019)
This chart tracks Lyell Immunopharma Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Lyell Immunopharma Inc (2019–2019)
Year-by-year Capital Reinvestment Ratio for Lyell Immunopharma Inc from 2019 to 2019. For live market cap and broader valuation context, see Lyell Immunopharma Inc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 0.41x | $39.47 Million | $16.05 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow